# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst Balaji Prasad maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and lowers the price target from...
IDEXX Laboratories reports Q1 EPS of $2.81 (up 10% Y/Y), with sales reaching $964M (7% increase). Revenue growth driven by Comp...
IDEXX Laboratories (NASDAQ:IDXX) reported quarterly earnings of $2.81 per share which beat the analyst consensus estimate of $2...
Elanco Animal Health settles with Ancora, expanding board to 14 members, including Ancora's nominees Craig Wallace and Kath...